Article info
PDFClinical/translational cancer immunotherapy
Original research
Generation and in vivo validation of an IL-12 fusion protein based on a novel anti-human FAP monoclonal antibody
- Correspondence to Dr Roberto De Luca; roberto.deluca{at}philogen.com
Citation
Generation and in vivo validation of an IL-12 fusion protein based on a novel anti-human FAP monoclonal antibody
Publication history
- Accepted August 30, 2022
- First published September 14, 2022.
Online issue publication
March 12, 2024
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.